Skip Navigation

Overview

  • Thank you for joining us for the two-day Symposium where we explored how Dana-Farber will transform the field of cancer care through discovery and innovation.

    This year’s dinner featured an engaging discussion with Dana-Farber’s President and CEO, Laurie H. Glimcher, MD, and Bank of America’s Chairman and CEO, Brian Moynihan. We also heard from Dana-Farber Leadership, and a lunch panel including Giovanni Caforio, MD, Chairman and CEO of Bristol-Myers Squibb, and John Maraganore, PhD, CEO of Alnylam Pharmaceuticals.

  • An Inside Look: 2018 Joint Visiting Committee Symposium
    Each year, members of Dana-Farber Cancer Institute’s Presidential Visiting Committees gather for a two-day symposium to hear updates from Institute leaders and physician-scientists on the latest advancements and achievements, and to discuss their ideas for securing more resources for Dana-Farber.

  • State of the Institute
    Laurie H. Glimcher, MD, Dana-Farber’s President & CEO, gives Visiting Committee members an update on the excellent progress in research and care initiatives at the Institute.

  • A Conversation with Brian Moynihan and Laurie H. Glimcher, MD
    Dana-Farber’s President & CEO, Laurie H. Glimcher, MD, sits down for a conversation with Brian Moynihan, Chairman and CEO, Bank of America about the economy, the global financial landscape, healthcare, and the application of new technologies to stay at the forefront of the industry.

  • Dana-Farber’s Strategic Plan: Launching a New Era
    Moderated by Dana-Farber’s President & CEO, Laurie H. Glimcher, MD, Lisa R. Diller, MD, William C. Hahn, MD, PhD, Lesley Solomon, and Eric P. Winer, MD, discuss what it will take to fulfill the goals outlined in the Strategic Plan.

  • Patient-Focused Drug Development: Engaging Patients to Spark Real Change
    Moderated by Dana-Farber’s President & CEO, Laurie H. Glimcher, MD, Giovanni Caforio, MD, George D. Demetri, MD, FACP, FASCO, Katherine A. Janeway, MD, MMSc, and John Maraganore, PhD, discuss how patient-focused drug development can accelerate new lifesaving medicines.


  • Related Information

    Dana-Farber Overview

    Jimmy-Fund Overview

    Dana-Farber Society Overview

    Dana-Farber 2018 Fact Book

    Giving Stock Overview